SPECTRI
Doctors are always looking for ways that they can improve the lives and health of their patients, including research studies. Below are details of a study currently looking for volunteers. Please use the contact details at the end of the page for more information.
Background
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)
Age related macular degeneration (AMD) is the leading cause of irreversible blindness in people aged 50 years or older in the developed world. The majority of the visual loss occurs in the advanced stage of AMD.
Geographic atrophy (GA) is one form of the condition, which is characterised by loss of blood vessels to the retina, layers of cells that contain pigment, and photoreceptors in the retina. The prevalence of GA increases exponentially with age and approximately quadruples per decade beyond 50 years of age.
The estimated prevalence of GA in populations of European ancestry at 70 years of age is 0.70%, rising to 2.91% at 80 years of age and 11.29% at 90 years of age. Currently, there are no approved treatments to prevent the worsening of GA or the associated decline in vision. Consequently, a significant unmet need exists for the treatment of this serious condition.
What is the aim of the study?
This study aims to assess the efficacy and safety of a 10 mg lampalizumab injection (into the side of the eye), given either 4 or 6 weekly, compared to a sham injection for a treatment period of approximately 2 years in patients with geographic atrophy secondary to age related macular degeneration.
Further information on this study is listed on the UK Clinical Trials Gateway website.
